LyGenesis raises $4m ahead of Phase 2a trials

LyGenesis raises $4m ahead of Phase 2a trials

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

New money for technology that uses lymph nodes as bioreactors to regrow functioning organs.

LyGenesis, a biotechnology company focused on organ regeneration, announced that it has completed a total of $4 million in private financing of convertible notes from Juvenescence, Ltd. and Longevity Vision Fund. This new funding comes after a $3m Series A from May 2018 according to Crunchbase.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2260

LyGenesis

Longevity level(s):

  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.
  • Level 8: Systemic aging reversal
    Therapeutic interventions that stop or reverse age-related damage throughout the whole body system at a cellular level. Including technologies such as mitochondrial transplant, senotherapeutics and partial cellular reprogramming.

Overview

LyGenesis is a clinical-stage regenerative medicine company developing a novel platform that leverages the body’s own lymph nodes as biological bioreactors to grow functioning ectopic organs. Using minimally invasive delivery of allogeneic donor cells, the company is advancing therapies designed to restore organ function and address diseases associated with organ failure, metabolic dysfunction, immune decline, and aging. Unlike traditional transplantation approaches, LyGenesis’ proprietary technology enables a single donor organ to potentially treat up to 50 patients, creating a scalable regenerative medicine solution that addresses the global shortage of transplantable organs while significantly expanding patient access. The platform is being developed across liver, pancreas, thymus, and kidney applications with therapeutic potential spanning end-stage organ disease, Type 1 diabetes, immune tolerance induction, immune system rejuvenation, and age-related degenerative conditions. By combining scalable manufacturing, minimally invasive delivery, and a novel approach that leverages the body’s own regenerative capacity, LyGenesis is developing a platform that has the potential to expand access to organ replacement therapies while addressing broader applications in immune function, metabolic disease, and age-related decline.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Phil Newman

Editor-in-Chief

Phil is Editor-in-Chief Longevity.Technology and founder of First Longevity which brings together international investors and Longevity start-ups.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Old dogs, new funding: Dog Aging Project fetches $29m from NIH

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE